Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
Launched by CANCER RESEARCH CAMPAIGN CLINICAL TRIALS CENTRE · May 21, 2004
Trial Information
Current as of March 21, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES: I. Assess the treatment-related neurologic and hematologic toxicities of patients aged 65 years and over with intermediate- or high-grade non-Hodgkin's lymphoma randomized to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) vs. MCOP (mitoxantrone, cyclophosphamide, vincristine, prednisolone). II. Compare the survival rate in these patients.
OUTLINE: Randomized study. The following acronyms are used: CHOP CTX/DOX/VCR/PRDL CTX Cyclophosphamide, NSC-26271 DHAD Mitoxantrone, NSC-301739 DOX Doxorubicin, NSC-123127 MCOP DHAD/CTX/VCR/PRDL PRDL Prednisolone, NSC-9900 VCR...
Gender
ALL
Eligibility criteria
- • DISEASE CHARACTERISTICS: Histologically confirmed intermediate- or high-grade non- Hodgkin's lymphoma of the following types: Diffuse centroblastic Diffuse immunoblastic B- and T-cell lymphoblastic Peripheral T-cell (mixed or large cell) and Ki-1 No Stage IA (nonbulky) disease suitable for radiotherapy alone
- • PATIENT CHARACTERISTICS: Age: 65 and over Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No severe ischemic heart disease No cardiomyopathy that would restrict doxorubicin use Other: No other serious medical conditions that would affect treatment outcome No prior malignancy except: Nonmelanomatous skin cancer Adequately treated in situ cervical cancer Sufficiently fit to receive treatment
- • PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: Not specified
Trial Officials
Eric Michael Bessell, MD, PhD, FRCP, FRCR
Study Chair
Nottingham City Hospital
About Cancer Research Campaign Clinical Trials Centre
The Cancer Research Campaign Clinical Trials Centre is a leading organization dedicated to advancing cancer research through rigorous clinical trials. Committed to improving patient outcomes, the Centre facilitates innovative studies that explore novel therapies and treatment strategies, collaborating with top-tier researchers and healthcare institutions. With a focus on scientific integrity and patient safety, the Centre aims to translate groundbreaking discoveries into effective clinical applications, ultimately enhancing the quality of care for cancer patients. Its comprehensive approach combines cutting-edge research methodologies with a commitment to ethical standards, fostering an environment that prioritizes both scientific excellence and patient well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nottingham, England, United Kingdom
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials